Variables
|
DFS
|
OS
|
---|
χ
2
|
P-value
|
χ
2
|
P-value
|
---|
Age (years)
|
≤50 vs. >50
|
0.058
|
0.810
|
0.436
|
0.509
|
Tumor size (cm)a
|
≤2 vs. >2, ≤5 vs. >5
|
2.515
|
0.284
|
2.608
|
0.271
|
Lymph node stage
|
negative vs. positive
|
11.706
|
0.001
|
8.803
|
0.003
|
Grade
|
G1 vs. G2 vs. G3
|
4.764
|
0.092
|
3.204
|
0.201
|
Clinical stagea
|
I vs. II vs. III and IV
|
10.343
|
0.006
|
8.576
|
0.014
|
Histological type
|
IDC vs. ILC vs. Others
|
0.588
|
0.745
|
0.883
|
0.643
|
Ki-67 LI
|
Low (≤14 %) vs. High (>14 %)
|
1.974
|
0.160
|
2.709
|
0.100
|
Chemotherapy
|
AC vs. AC-T vs. Others vs. None
|
0.664
|
0.882
|
1.194
|
0.754
|
Radiotherapy
|
No vs. Yes
|
0.091
|
0.763
|
0.002
|
0.963
|
PELP1 status
|
Low vs. High
|
2.887
|
0.089
|
3.182
|
0.074
|
- Abbreviations: LN, lymph node; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; Ki-67 LI, Ki-67 label index; AC, Adriamycin/Cyclophosphamide; AC-T, Adriamycin/Cyclophosphamide-Taxol; DFS, disease-free survival; OS, overall survival
- Note: afor the variable, data for two cases are unavailable from medical records